主页 > 医药生命 >
【medical-news】Ezetimibe/Simvastatin 降低糖尿病人LDL
NEW YORK (Reuters Health) Dec 19 - Ezetimibe/simvastatin provides superior lipid-modifying benefits compared with atorvastatin monotherapy in patients with type 2 diabetes and hypercholesterolemia.
In a double-blind, randomized, multicenter study, Dr. Ronald B. Goldberg, of the University of Miami, Florida, and colleagues compared the safety and efficacy of the recommended starting dose and the next highest dose of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.
One thousand two hundred twenty-two adults were randomized to the recommended starting dose of ezetimibe/simvastatin (10/20 mg/d) versus atorvastatin (10 mg/d or 20 mg/d), or the next highest dose of ezetimibe/simvastatin (10/40 mg/d) versus atorvastatin (40 mg/d). The treatment was given daily for 6 weeks.
The main efficacy end point was the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) levels. The secondary efficacy measure was the proportion of patients who attained LDL-C levels less than 70 mg/dL.
Other efficacy measures included the proportion of patients who attained LDL-C levels less than 100 mg/dL; percent change from baseline in total cholesterol, high-density lipoprotein cholesterol (HDL-C), non-HDL-C, and triglyceride levels; and changes in high-sensitivity C-reactive protein. The results of the study are published in the December issue of Mayo Clinic Proceedings.
Patients treated with ezetimibe/simvastatin, 10/20 mg/d achieved significantly greater mean reductions in LDL-C levels (-53.6%) than those treated with atorvastatin, 10 mg/d (-38.3%; p < 0.001) or 20 mg/d (-44.6%; p < 0.001).
Significantly greater mean reductions were also observed in patients treated with the higher dose of ezetimibe/simvastatin, 10/40 mg/d (-57.6%) compared to higher dose of atorvastatin, 40 mg (-50.9%; p < 0.001).
Ezetimibe/simvastatin was also superior to atorvastatin in attainment of LDL-C levels less than 70 mg/dL and 100 mg/dL.
Compared with atorvastatin, ezetimibe/simvastatin resulted in greater increases from baseline in HDL-C levels. Ezetimibe/simvastatin was also superior in lowering total cholesterol and non-HDL-C levels.
"Ezetimibe/simvastatin, 10/20 mg/d, decreased levels of high-sensitivity C-reactive protein and triglycerides significantly more than atorvastatin, 10 mg/d (p = 0.02)," Dr. Goldberg's team explains. "At the other dose, reductions in high-sensitivity C-reactive protein and triglyceride levels were comparable."
There were no significant differences in adverse clinical or laboratory events between the ezetimibe/simvastatin groups and the atorvastatin groups.
Dr. Goldberg's group concludes that "ezetimibe/simvastatin was consistently superior to atorvastatin in reducing LDL-C levels at both the recommended usual starting and next highest doses in patients with type 2 diabetes and hypercholesterolemia."
http://www.medscape.com/viewarticle/549631 我认领这个,如果48小时不能完成,请各位战友帮忙. Ezetimibe/Simvastatin Lowers LDL-C More Than Atorvastatin in Diabetics
与Atorvastatin相比，Ezetimibe/Simvastatin降低糖尿病患者的LDL-C效果更优
NEW YORK (Reuters Health) Dec 19 - Ezetimibe/simvastatin provides superior lipid-modifying benefits compared with atorvastatin monotherapy in patients with type 2 diabetes and hypercholesterolemia.
纽约（路透社健康频道）12月19日讯：与atorvastatin相比， Ezetimibe/simvastatin在降低2型糖尿病和高血脂症患者体内的血脂水平的作用更优。
In a double-blind, randomized, multicenter study, Dr. Ronald B. Goldberg, of the University of Miami, Florida, and colleagues compared the safety and efficacy of the recommended starting dose and the next highest dose of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.
佛罗里达，买啊迷大学的Ronald B. Goldberg博士及他的同事，经过双盲，随机，多中心联合研究后，比较了ezetimibe/simvastatin以及atorvastatin在推荐剂量和最高耐受量下，对2型糖尿病患者和高血脂患者治疗的效果和安全性。
One thousand two hundred twenty-two adults were randomized to the recommended starting dose of ezetimibe/simvastatin (10/20 mg/d) versus atorvastatin (10 mg/d or 20 mg/d), or the next highest dose of ezetimibe/simvastatin (10/40 mg/d) versus atorvastatin (40 mg/d). The treatment was given daily for 6 weeks.
1222名受试者被随机分到到了4组：ezetimibe/simvastatin推荐剂量组(10/20 mg/d)、atorvastatin 推荐剂量组(10或20 mg/d)、ezetimibe/simvastatin最大耐受组(10/40 mg/d)、atorvastatin最大耐受组(40mg/d)。
The main efficacy end point was the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) levels. The secondary efficacy measure was the proportion of patients who attained LDL-C levels less than 70 mg/dL.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-04-06 17:16
医学,生命科学网